資料2

アンチバイオグラム
地域別2024

Escherichia coli 大腸菌
Klebsiella pneumoniae subsp. pneumoniae
クレブシエラ菌
Streptococcus pneumoniae 肺炎球菌（髄液検体以外）
Streptococcus pyogenes 溶連菌
Haemophilus influenzae インフルエンザ菌
Staphylococcus aureus 黄色ブドウ球菌 (耐性比率)

全国データは、JANIS （Japan Nosocomial Infections Surveillance 厚生労働省院内感染対策サーベイランス事業）の資料に基づいたものです

S：感受性、I：中間、R：耐性、NS：非感受性

腸内細菌目細菌の固有耐性

CLSI M100-ED33:2024 Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition **より引用**

Antimicrobial Agent → / Organism ↓	Ampicillin	Amoxicillin-clavulanate	Ampicillin-sulbactam	Ticarcillin	Cephalosporins I: Cefazolin, Cephalothin	Cephamycins: Cefoxitin, Cefotetan	Cephalosporins II: Cefuroxime	Imipenem	Tetracyclines	Tigecycline	Nitrofurantoin	Polymyxin B Colistin	Aminoglycosides
Citrobacter freundii	R	R	R		R	R	R						
Citrobacter koseri, Citrobacter amalonaticus group[a]	R			R									
Enterobacter cloacae complex[b]	R	R	R		R	R							
Escherichia coli	There is no intrinsic resistance to β-lactams in this organism.												
Escherichia hermannii	R			R									
Hafnia alvei	R	R	R		R	R						R[c]	
Klebsiella (formerly *Enterobacter*) *aerogenes*	R	R	R		R	R							
Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella variicola	R			R									
Morganella morganii	R	R			R		R	[d]		R	R	R	
Proteus mirabilis	There is no intrinsic resistance to penicillins and cephalosporins in this organism.							[d]	R	R	R	R	
Proteus penneri	R				R		R	[d]	R	R	R	R	
Proteus vulgaris	R				R		R	[d]	R	R	R	R	
Providencia rettgeri	R	R			R			[d]	R	R	R	R	
Providencia stuartii	R	R			R			[d]	R	R	R	R	[e]
Raoultella spp.[f]	R			R									
Salmonella and *Shigella* spp.	There is no intrinsic resistance to β-lactams in these organisms; refer to **WARNING** below for reporting.												
Serratia marcescens	R	R	R		R	R	R				R	R	
Yersinia enterocolitica	R	R		R	R								

WARNING: For *Salmonella* spp. and *Shigella* spp., aminoglycosides, first– and second–generation cephalosporins, and cephamycins may appear active *in vitro* but are not effective clinically and should not be reported as susceptible.

Footnotes

a. *Citrobacter amalonaticus* group includes *C. amalonaticus*, *C. farmeri*, and *C. sedlakii*.

b. *E. cloacae* complex includes *Enterobacter asburiae*, *Enterobacter cloacae*, and *Enterobacter hormaechei*. Other members of the complex include *Enterobacter kobei* and *Enterobacter ludwigii*, for which antimicrobial susceptibility testing data are not available.

c. Colistin and polymyxin B resistance also applies to *Hafnia paralvei*.

d. *Proteus* spp., *Providencia* spp., and *Morganella* spp. may have elevated minimal inhibitory concentrations to imipenem by mechanisms other than by production of carbapenemases. Isolates that test as susceptible should be reported as susceptible.

e. *P. stuartii* should be considered resistant to gentamicin, netilmicin, and tobramycin but not intrinsically resistant to amikacin.

f. *Raoultella* spp. includes *R. ornithinolytica*, *R. terrigena*, and *R. planticola*.

NOTE 1: Cephalosporins III, cefepime, cefiderocol, aztreonam, ticarcillin–clavulanate, piperacillin–tazobactam, imipenem–relebactam, ceftazidime–avibactam, meropenem–vaborbactam, and the carbapenems are not listed because there is no intrinsic resistance in Enterobacterales.

NOTE 2: Enterobacterales are also intrinsically resistant to clindamycin, daptomycin, fusidic acid, glycopeptides (vancomycin), lipoglycopeptides (oritavancin, teicoplanin, telavancin), linezolid, tedizolid, quinupristin–dalfopristin, rifampin, and macrolides (erythromycin, clarithromycin, and azithromycin). However, there are some exceptions with macrolides (eg, *Salmonella* and *Shigella* spp. with azithromycin).

【データ収集期間】

2024年1月から3月までの3ヶ月間（入院・外来検体）の菌株数

JANISデータは2023年（外来検体）と比較した

【データ提供医療機関数（カッコ内はクリニック）】

東部	20施設（3施設）	9540株（7株）
中部	18施設（4施設）	13415株（51株）
西部	22施設	11702株
合計	60施設（7施設）	34658株

【分離菌上位菌種（赤字はアンチバイオグラム作成対象）】

	菌名_2024	西部	中部	東部	総計
1	*Escherichia coli*	1,953	2,475	1,701	6,129
2	*MSSA*	1204	1,384	869	3,457
3	*Klebsiella pneumoniae subsp. pneumoniae*	787	991	701	2,479
4	*Pseudomonas aeruginosa*	805	958	691	2,454
5	*MRSA*	785	949	561	2,295
6	*Enterococcus faecalis*	549	665	589	1,803
7	*Streptococcus agalactiae*	497	417	392	1,306
8	*Staphylococcus epidermidis*	479	367	277	1123
9	*Klebsiella oxytoca*	258	290	223	771
10	*Enterococcus faecium*	167	313	262	742
11	*Corynebacterium spp.*	198	193	279	670
12	*Proteus mirabilis*	146	325	159	630
13	*Haemophilus influenzae*	247	200	101	548
14	*Staphylococcus ,coagulase negative (CNS)*	67	235	211	513
15	*Enterobacter cloacae*	128	202	156	486
16	*Serratia marcescens subsp. marcescens*	124	183	177	484
17	*Klebsiella aerogenes*	139	151	167	457
18	*Streptococcus spp.*	255	85	76	416
19	*α－Streptococcus*	69	189	108	366
20	*Streptococcus anginosus*	171	97	48	316
21	*Citrobacter koseri*	78	149	77	304
22	*Morganella morganii subsp. morganii*	102	101	91	294
23	*Streptococcus pyogenes*	142	78	58	278
24	*Streptococcus pneumoniae*	106	116	55	277

【*Escherichia coli*】 大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】 大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】 大腸菌

S:感受性、I :中間、R:耐性、NS:非感受性





CLSI M100-ED33:2023 Performance Standards for Antimicrobial Susceptibility Testing, 33rd Editionでは、大腸菌に対するFOMの判定基準は、UTIのみに設定されています。

【 *Klebsiella pneumoniae subsp. pneumoniae*】 クレブシエラ菌

S:感受性、I :中間、R:耐性、NS:非感受性







【 *Klebsiella pneumoniae* 】　クレブシエラ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pneumoniae*（髄液検体以外）】 肺炎球菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pneumoniae*（髄液検体以外）】肺炎球菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pyogenes* 】溶連菌

S:感受性、I:中間、R:耐性、NS:非感受性







【 *Streptococcus pyogenes*】溶連菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I ：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】インフルエンザ菌

S：感受性、I ：中間、R：耐性、NS：非感受性



【 *Staphylococcus aureus* 】 黄色ブドウ球菌
静岡県2024年1-3月期とJANIS2023年との比較



【 バンコマイシン耐性MRSA 患者数】
なし

【 VCM非感受性*Enterococcus faecium* 患者数】
E. faecium
東部　　38名　7施設